These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

896 related items for PubMed ID: 17825686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.
    Clin Cancer Res; 2007 Mar 01; 13(5):1367-73. PubMed ID: 17332278
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug 01; 16(90):138-41. PubMed ID: 17724833
    [Abstract] [Full Text] [Related]

  • 4. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R.
    Oncologist; 2007 Jan 01; 12(1):107-13. PubMed ID: 17227905
    [Abstract] [Full Text] [Related]

  • 5. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ.
    Cancer Chemother Pharmacol; 2010 Jul 01; 66(2):357-71. PubMed ID: 19967539
    [Abstract] [Full Text] [Related]

  • 6. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM, Szczylik C, Rini B.
    Expert Rev Anticancer Ther; 2014 Sep 01; 14(9):983-99. PubMed ID: 25066545
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
    J Oncol Pharm Pract; 2007 Mar 01; 13(1):5-15. PubMed ID: 17621562
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib.
    Deeks ED, Keating GM.
    Drugs; 2006 Mar 01; 66(17):2255-66; discussion 2267-8. PubMed ID: 17137406
    [Abstract] [Full Text] [Related]

  • 10. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A.
    J Steroid Biochem Mol Biol; 2008 Feb 01; 108(3-5):261-6. PubMed ID: 17945482
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib in solid tumors.
    Gan HK, Seruga B, Knox JJ.
    Expert Opin Investig Drugs; 2009 Jun 01; 18(6):821-34. PubMed ID: 19453268
    [Abstract] [Full Text] [Related]

  • 12. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM, Nystrom KK.
    Clin Ther; 2012 Mar 01; 34(3):511-20. PubMed ID: 22341567
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY, Korean Cancer Study Group, Genitourinary & Gynecology Cancer Committee.
    Eur J Cancer; 2014 Mar 23; 50(4):746-52. PubMed ID: 24332573
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
    Schöffski P, Bukowski R, Flodgren P, Ravaud A.
    Ann Oncol; 2009 May 23; 20 Suppl 1():i25-i30. PubMed ID: 19430005
    [Abstract] [Full Text] [Related]

  • 16. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb 23; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 17. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
    Theou-Anton N, Faivre S, Dreyer C, Raymond E.
    Drug Saf; 2009 Feb 23; 32(9):717-34. PubMed ID: 19670913
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib.
    Heng DY, Kollmannsberger C.
    Recent Results Cancer Res; 2010 Jun 07; 184():71-82. PubMed ID: 20072832
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B.
    Expert Rev Anticancer Ther; 2010 Mar 07; 10(3):305-17. PubMed ID: 20214511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.